Takeda's Response to COVID-19 If you were diagnosed with COVID-19 and have recovered, you may be able to help in furthering research into a potential therapy for others by donating your plasma.

A Swedish Observational Study on Vedolizumab Assessing Effectiveness And Healthcare Resource Utilization in Patients with Inflammatory Bowel Disease (IBD)

IDENTIFIERS
Trial Protocol: Vedolizumab-5008
EUPAS: EUPAS22735
PURPOSE

This is a prospective, multi-center, observational and cohort study for patients with IBD. This study will assess the effectiveness of vedolizumab for achieving clinical response at Week 12 and remission at Week 52 in participants with confirmed and active disease of ulcerative colitis (UC) and Crohn’s disease (CD), and will assess the long term effectiveness of vedolizumab treatment among 3 months responders or remitters in clinical practice. 

Recruiting
SE

Trial at a glance

What medical condition is being studied?   Inflammatory Bowel Disease
How many participants are being enrolled?   300
When is the trial being conducted?   

Key requirements

Sex   
All
Age   
From 18 Years
Accepts Healthy Volunteers?   
No

Trial Details / Participation Requirements

CLICK TO EXPANDCLICK TO COLLAPSE
Trial Type:   Observational